Neuren Pharmaceuticals Limited
ASX:NEU.AX
12.27 (AUD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 231.925 | 14.553 | 3.197 | 0.717 | 0.495 | 13.99 | 0.631 | 3.15 | 1.673 | 2.931 | 4.794 | 0 | 0 | 4.648 | 5.003 | 2.274 | 0.944 | 0.173 | 0.43 | 1.4 | 2.836 | 2.121 |
| Cost of Revenue
| 26.751 | 0.01 | 0.008 | 0.006 | 0.004 | 6.101 | 0.078 | 0.08 | 0.09 | 10.016 | 8.653 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 205.174 | 14.543 | 3.189 | 0.711 | 0.491 | 7.889 | 0.553 | 3.07 | 1.583 | -7.085 | -3.859 | 0 | 0 | 4.648 | 5.003 | 2.274 | 0.944 | 0.173 | 0.43 | 1.4 | 2.836 | 2.121 |
| Gross Profit Ratio
| 0.885 | 0.999 | 0.997 | 0.992 | 0.992 | 0.564 | 0.876 | 0.975 | 0.946 | -2.417 | -0.805 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 26.751 | 12.712 | 9.516 | 7.763 | 9.858 | 6.101 | 5.136 | 13.325 | 14.132 | 10.016 | 8.717 | 0 | 5.327 | 7.016 | 3.213 | 8.65 | 10.364 | 8.5 | 8.676 | 5.589 | 0 | 0 |
| General & Administrative Expenses
| 5.946 | 3.437 | 1.914 | 1.763 | 1.713 | 2.074 | 1.568 | 2.726 | 3.12 | 2.537 | 2.969 | 2.59 | 2.425 | 1.724 | 0.92 | 1.801 | 2.47 | 2.545 | 2.224 | 1.773 | 0 | 0 |
| Selling & Marketing Expenses
| -0.017 | -0.01 | -0.008 | -0.006 | -0.004 | 0 | -0.078 | -0.964 | 1.232 | 0.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.929 | 3.427 | 1.906 | 1.757 | 1.709 | 2.074 | 1.49 | 1.762 | 3.03 | 2.537 | 2.969 | 2.59 | 2.425 | 1.724 | 0.92 | 1.801 | 2.47 | 2.545 | 2.224 | 1.773 | 0 | 0 |
| Other Expenses
| 0.225 | 1.389 | 3.595 | 0.186 | 0.366 | -2.514 | 9.945 | 1.121 | 2.771 | 3.807 | 3.737 | 4.088 | 3.385 | -0.23 | 0.164 | 0.355 | 0.938 | 1.56 | 2.179 | 0.814 | -8.161 | -7.35 |
| Operating Expenses
| 32.68 | 16.139 | 11.422 | 9.52 | 11.567 | 5.034 | 6.626 | 15.087 | 17.162 | 12.653 | 12.361 | 9.478 | 8.252 | 9.447 | 5.056 | 12.192 | 14.217 | 12.351 | 11.72 | 8.419 | 0.514 | 0.525 |
| Operating Income
| 199.228 | -1.596 | -11.43 | -9.526 | -11.571 | 5.815 | -6.704 | -15.167 | -17.252 | -9.722 | -9.449 | -9.478 | -4.735 | -4.989 | 0.131 | -9.434 | -12.092 | -12.178 | -10.515 | -7.605 | 2.322 | 1.596 |
| Operating Income Ratio
| 0.859 | -0.11 | -3.575 | -13.286 | -23.376 | 0.416 | -10.624 | -4.815 | -10.312 | -3.317 | -1.971 | 0 | 0 | -1.073 | 0.026 | -4.148 | -12.807 | -70.407 | -24.472 | -5.433 | 0.819 | 0.753 |
| Total Other Income Expenses Net
| 5.895 | 0.916 | 0.439 | -0.384 | 0.26 | -2.742 | 9.361 | 1.309 | 3.106 | 3.776 | 0.825 | 4.088 | 3.385 | -0.23 | 0.009 | -5.544 | 0.938 | 1.56 | 2.179 | 0.814 | -8.161 | -7.35 |
| Income Before Tax
| 205.123 | -0.68 | -10.991 | -9.91 | -11.311 | 3.073 | 2.657 | -13.858 | -14.146 | -8.316 | -11.337 | -5.19 | -4.741 | -4.991 | -0.027 | -15.358 | -12.153 | -10.116 | -8.291 | -5.694 | -5.647 | -5.458 |
| Income Before Tax Ratio
| 0.884 | -0.047 | -3.438 | -13.821 | -22.851 | 0.22 | 4.211 | -4.399 | -8.455 | -2.837 | -2.365 | 0 | 0 | -1.074 | -0.005 | -6.753 | -12.871 | -58.485 | -19.296 | -4.068 | -1.991 | -2.573 |
| Income Tax Expense
| 48.042 | -0.864 | -3.197 | -0.717 | -0.495 | -0.446 | -0.631 | -1.844 | -0.749 | -0.019 | 1.849 | -4.385 | -0.091 | -0.097 | 0.029 | 0.061 | 0.061 | -2.062 | 0.018 | -5.694 | -5.647 | -5.458 |
| Net Income
| 157.081 | 0.184 | -7.794 | -9.193 | -10.816 | 3.073 | 3.288 | -12.014 | -13.397 | -8.297 | -11.299 | -5.094 | -4.65 | -4.893 | 0.1 | -15.419 | -12.153 | -10.116 | -8.308 | -5.694 | -5.647 | -5.458 |
| Net Income Ratio
| 0.677 | 0.013 | -2.438 | -12.821 | -21.851 | 0.22 | 5.211 | -3.814 | -8.008 | -2.831 | -2.357 | 0 | 0 | -1.053 | 0.02 | -6.78 | -12.871 | -58.485 | -19.337 | -4.068 | -1.991 | -2.573 |
| EPS
| 1.24 | 0.002 | -0.066 | -0.086 | -0.11 | 0.031 | 0.036 | -2.84 | -0.16 | -0.11 | -0.18 | -0.087 | -0.12 | -0.23 | 0.007 | -1.25 | -0.99 | -0.82 | -0.67 | -0.46 | -0.46 | -0.44 |
| EPS Diluted
| 1.2 | 0.001 | -0.066 | -0.086 | -0.11 | 0.031 | 0.035 | -2.84 | -0.16 | -0.11 | -0.18 | -0.087 | -0.12 | -0.23 | 0.007 | -1.25 | -0.99 | -0.82 | -0.67 | -0.46 | -0.46 | -0.44 |
| EBITDA
| 199.245 | -1.586 | -11.422 | -9.52 | -11.567 | 5.892 | -6.626 | -15.087 | -17.162 | -12.522 | -9.021 | -9.117 | -4.381 | -4.587 | 0.637 | -8.312 | -11.202 | -11.392 | -10.47 | -6.069 | 2.836 | 2.121 |
| EBITDA Ratio
| 0.859 | -0.109 | -3.573 | -13.278 | -23.368 | 0.421 | -10.501 | -4.79 | -10.258 | -4.272 | -1.882 | 0 | 0 | -0.987 | 0.127 | -3.655 | -11.865 | -65.861 | -24.367 | -4.336 | 1 | 1 |